Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women

References

• Al-Azzawi F, Palacios S. Hormonal changes during menopause. Maturitas 2009;63:135–7
   PubMed Web of Science ®Google Scholar
• Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril 1995;64:740–5
   PubMed Web of Science ®Google Scholar
• Gold EB, Sternfeld B, Kelsey JL, Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol 2000;152:463–73
   PubMed Web of Science ®Google Scholar
• Dratva J, Gómez Real F, Schindler C, Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies. Menopause 2009;16:385–94
   PubMed Web of Science ®Google Scholar
• Meschia M, Pansini F, Modena AB, Determinants of age at menopause in Italy: results from a large cross-sectional study. ICARUS Study Group. Italian Climacteric Research Group Study. Maturitas 2000;34:119–25
   PubMed Web of Science ®Google Scholar
• Biri A, Bakar C, Maral M, Karabacak O, Bumin MA. Women with and without menopause over age of 40 in Turkey: consequences and treatment options. Maturitas 2005;50: 167–76
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin S-Q, Wei Y, Gao H-L, Wu Z-L. Menopause-specific quality of life satisfaction in community-dwelling menopausal women in China. Gynecol Endocrinol 2007;23: 166–72
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin S-Q, Wei Y, Gao H-L, Wang S-H, Wu Z-L. Impact of menopause on quality of life in community-based women in China. Menopause 2008;15:144–9
   PubMed Web of Science ®Google Scholar
• Boulet MJ, Oddens BJ, Lehert P, Vemer HM, Visser A. Climacteric and menopause in seven south-east Asian countries. Maturitas 1994;19:157–76
   PubMed Web of Science ®Google Scholar
• Green R, Santoro N. Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Womens Health (Lond Engl) 2009;5:127–33
   PubMedGoogle Scholar
• Cobin RH, Futterweit W, Ginzburg SB, et al.; AACE Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006;12:315–37
   PubMedGoogle Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55
   PubMed Web of Science ®Google Scholar
• NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens State Sci Statements 2005;22:1–38
   Google Scholar
• Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas 2007;58:348–58
   PubMed Web of Science ®Google Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
   PubMedGoogle Scholar
• Liu J, Eden J. Experience and attitudes toward menopause in Chinese women living in Sydney – a cross sectional survey. Maturitas 2007;58:359–65
   PubMed Web of Science ®Google Scholar
• Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4):CD002978
   PubMedGoogle Scholar
• Board of the International Menopause Society.IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–9
   PubMed Web of Science ®Google Scholar
• Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review. Clin Interv Aging 2009;4:59–62
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716–27
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005;8(Suppl 3):4–12
   PubMed Web of Science ®Google Scholar
• Ylikorkala O. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Climacteric 2005;8(Suppl 3):1–3
   PubMed Web of Science ®Google Scholar
• Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas 2007;57:361–9
   PubMed Web of Science ®Google Scholar
• Preston RA, Norris PM, Alonso AB, Ni P, Hanes V, Karara AH. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007;14:408–14
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. A review of the cardiovascular and breast actions of drospirenone in preclinical studies. Climacteric 2010;13:22–33
   PubMed Web of Science ®Google Scholar
• Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189–96
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ. No ADM 76-338). Rockville, MD, USA: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:218–22
   Google Scholar
• Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003;9:387–96
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al.; Women's Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105:1063–73
   PubMed Web of Science ®Google Scholar
• Ho SC, Wu S, Chan SG, Sham A. Menopausal transition and changes of body composition: a prospective study in Chinese perimenopausal women. Int J Obes (Lond) 2010;34:1265–74
   PubMed Web of Science ®Google Scholar